Drugs with this side effect as MedDRA Preferred Term
- 17-hydroxyprogesterone
- 2-hydroxysuccinaldehyde
- 5-aza-2'-deoxycytidine
- BCNU
- Pulmonary embolism: 8.33%
- BPTI
- CAS 76095-16-4
- CAS 76420-72-9
- Pulmonary embolism: postmarketing
- EACA
- Estrofem
- FK463
- Glat copolymer
- Pulmonary embolism: postmarketing
- Goserelin
- Pulmonary embolism: postmarketing, 0% - 1.27%
- K779
- L-Dmp
- Leuprorelin
- Pulmonary embolism: postmarketing
- Lisinopril
- Lutalyse
- Meropenem anhydrous
- Nafarelin
- Pulmonary embolism: postmarketing
- Oestrogen
- Pulmonary embolism: uncommon
- Photofrin
- Promacta
- Refludan
- Romidepsin
- SU5416
- Supremon
- Trisequens
- Zyprexa Relprevv
- Pulmonary embolism: very rare
- acamprosate
- allopurinol
- amisulpride
- Pulmonary embolism: postmarketing
- anastrozole
- aprepitant
- argatroban
- Pulmonary embolism: 4% - 13%
- aripiprazole
- asenapine
- axitinib
- Pulmonary embolism: 2% - 2.2%
- baclofen
- bazedoxifene
- Pulmonary embolism: uncommon
- benzathine penicillin
- boceprevir
- Pulmonary embolism: uncommon
- bortezomib
- bupropion
- Pulmonary embolism: postmarketing, rare
- cabozantinib
- capecitabine
- carbamazepine
- Pulmonary embolism: very rare
- celecoxib
- cevimeline
- ciprofloxacin
- Pulmonary embolism: postmarketing
- citalopram
- Pulmonary embolism: postmarketing, rare
- cladribine
- Pulmonary embolism: very rare
- clarithromycin
- clomiphene citrate
- Pulmonary embolism: postmarketing
- clopidogrel
- clozapine
- Pulmonary embolism: postmarketing
- conjugated estrogens
- Pulmonary embolism: postmarketing
- copolymer 1
- Pulmonary embolism: postmarketing
- crizotinib
- Pulmonary embolism: 1.2% - 6%
- cyclophosphamide
- Pulmonary embolism: postmarketing
- cyproterone acetate
- dalteparin
- Pulmonary embolism: 2.29% - 2.31%
- dasatinib
- Pulmonary embolism: postmarketing
- deferiprone
- Pulmonary embolism: postmarketing
- diatrizoate
- docetaxel
- Pulmonary embolism: very rare, postmarketing
- doxorubicin
- Pulmonary embolism: postmarketing, uncommon
- eribulin
- ertapenem
- estradiol
- Pulmonary embolism: postmarketing
- estradiol cypionate
- estradiol valerate
- estriol
- estrone
- everolimus
- Pulmonary embolism: postmarketing, uncommon
- exemestane
- fenofibrate
- Pulmonary embolism: uncommon
- fentanyl
- fluoxetine
- Pulmonary embolism: postmarketing
- fluphenazine decanoate
- flurbiprofen
- flutamide
- fosphenytoin
- Pulmonary embolism: infrequent
- gabapentin
- gadobenate dimeglumine
- glucose
- ifosfamide
- Pulmonary embolism: postmarketing
- irinotecan
- ketorolac tromethamine
- lasofoxifene
- Pulmonary embolism: uncommon
- lenalidomide
- Pulmonary embolism: postmarketing, common, 1.49% - 3.97%
- letrozole
- leuprorelin acetate
- lomefloxacin
- lurasidone
- medroxyprogesterone
- Pulmonary embolism: postmarketing
- medroxyprogesterone acetate
- Pulmonary embolism: postmarketing
- megestrol
- Pulmonary embolism: postmarketing
- megestrol acetate
- memantine
- Pulmonary embolism: postmarketing, infrequent
- meropenem
- methotrexate
- mirtazapine
- Pulmonary embolism: postmarketing, rare
- misoprostol
- Pulmonary embolism: postmarketing
- morphine
- mycophenolate mofetil
- naltrexone
- norethisterone
- ofloxacin
- ogen
- olanzapine
- Pulmonary embolism: very rare, postmarketing, rare
- paclitaxel
- Pulmonary embolism: postmarketing, rare
- Pulmonary thromboembolism
- paliperidone
- Pulmonary embolism: very rare, postmarketing
- parecoxib
- paroxetine
- pazopanib
- pemetrexed
- penicillin
- pentostatin
- pergolide
- Pulmonary embolism: infrequent
- phenytoin
- Pulmonary embolism: infrequent
- pomalidomide
- ponatinib
- posaconazole
- pramipexole
- pregabalin
- Pulmonary embolism: infrequent
- prochlorperazine
- progesterone
- propericiazine
- prostacyclin
- quetiapine
- rabeprazole
- raloxifene
- Pulmonary embolism: uncommon
- rapamycin
- Pulmonary embolism: postmarketing
- ribavirin
- riluzole
- risperidone
- Pulmonary embolism: postmarketing, rare
- rivastigmine
- Pulmonary embolism: infrequent
- rofecoxib
- ropinirole
- ropivacaine
- sitaxsentan
- sodium tetradecyl sulphate
- sumatriptan
- Pulmonary embolism: postmarketing
- sunitinib
- Pulmonary embolism: postmarketing
- tamoxifen
- temozolomide
- Pulmonary embolism: uncommon, 1%
- temsirolimus
- testosterone
- Pulmonary embolism: postmarketing
- thalidomide
- Pulmonary embolism: 6.84%
- tibolone
- tizanidine
- tolcapone
- Pulmonary embolism: infrequent
- tolvaptan
- topiramate
- Pulmonary embolism: rare, infrequent
- topotecan
- toremifene
- Pulmonary embolism: 0.498% - 1.81%
- trabectedin
- tramadol
- Pulmonary embolism: postmarketing
- tranexamic acid
- Pulmonary embolism: postmarketing, 0.8% - 1%
- trans 4-cyclohexyl-L-proline
- Recurrent pulmonary embolism
- treprostinil
- valdecoxib
- varenicline
- venlafaxine
- vigabatrin
- Pulmonary embolism: postmarketing
- vinflunine
- vinorelbine
- Pulmonary embolism: postmarketing
- voriconazole
- vorinostat
- zaleplon
- ziprasidone
- zolpidem
- zonisamide
|
Drugs with this indication
|